Humana key statistics and ratios
In fiscal 2025, Humana had return on equity of 7.0%, an operating margin of 2.1%, debt equal to 70.1% of equity and a current ratio of 2.00. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 5.6% | 5.5% | 6.4% | 5.2% | 5.0% | 4.9% | 4.3% | 3.2% | 7.9% | 5.4% | 4.9% | 6.5% | 3.8% | 4.1% | 3.8% | 2.2% | 2.1% | 1.9% |
| Net margin | 3.4% | 3.3% | 3.9% | 3.1% | 3.0% | 2.4% | 2.4% | 1.1% | 4.6% | 3.0% | 4.2% | 4.4% | 3.5% | 3.0% | 2.3% | 1.0% | 0.9% | 0.9% |
| Free-cash-flow margin | 4.0% | 6.0% | 4.7% | 3.9% | 3.1% | 2.2% | 0.6% | 2.6% | 6.6% | 2.7% | 7.0% | 6.1% | 1.1% | 3.7% | 2.8% | 2.0% | 0.3% | 1.3% |
| Return on equity | 18.0% | 17.3% | 18.9% | 14.5% | 13.6% | 12.1% | 12.8% | 5.8% | 23.9% | 16.8% | 24.4% | 26.1% | 19.7% | 17.9% | 15.8% | 7.4% | 7.0% | 6.9% |
| Return on assets | 7.3% | 7.3% | 8.4% | 6.5% | 6.0% | 5.2% | 5.3% | 2.5% | 9.3% | 6.4% | 9.9% | 10.5% | 7.4% | 6.4% | 5.5% | 2.6% | 2.5% | 2.4% |
| Asset turnover | 2.17 | 2.22 | 2.18 | 2.08 | 2.03 | 2.19 | 2.25 | 2.17 | 2.05 | 2.16 | 2.38 | 2.41 | 2.09 | 2.12 | 2.36 | 2.52 | 2.72 | 2.75 |
| Current ratio | 1.76 | 1.76 | 1.85 | 1.84 | 1.95 | 2.08 | 1.93 | 2.07 | 1.85 | 1.68 | 1.82 | 1.76 | 1.62 | 1.52 | 1.59 | 1.76 | 2.00 | 1.74 |
| Debt to equity | 29.1% | 30.0% | 24.4% | 33.2% | 32.2% | 43.1% | 39.6% | 38.3% | 50.0% | 59.7% | 47.1% | 48.5% | 77.7% | 72.7% | 71.7% | 71.6% | 70.1% | 74.2% |
| Interest cover (operating income ÷ interest) | 16.1x | 17.7x | 21.5x | 19.2x | 14.7x | 12.3x | 12.6x | 9.2x | 17.6x | 14.2x | 13.2x | 17.6x | 9.7x | 9.5x | 8.1x | 3.9x | 4.3x | 3.8x |
| Effective tax rate | 35.1% | 37.2% | 36.5% | 36.1% | 35.9% | 47.1% | 47.5% | 60.4% | 39.1% | 18.9% | 22.0% | 28.0% | 14.2% | 21.4% | 25.1% | 25.5% | 17.4% | 19.2% |
| SG&A as % of revenue | 13.1% | 13.0% | 14.6% | 14.9% | 15.4% | 15.8% | 13.4% | 13.2% | 12.2% | 13.2% | 11.4% | 13.0% | 12.2% | 13.6% | 12.4% | 11.6% | 11.9% | 11.3% |
| Capital spending as % of revenue | 0.6% | 0.7% | 0.9% | 1.0% | 1.1% | 1.1% | 1.0% | 1.0% | 1.0% | 1.1% | 1.1% | 1.2% | 1.6% | 1.2% | 0.9% | 0.5% | 0.4% | 0.4% |
| Free cash flow ÷ net income | 118.9% | 183.8% | 122.1% | 123.8% | 103.6% | 95.0% | 27.0% | 229.5% | 144.1% | 92.8% | 168.0% | 138.8% | 31.4% | 123.0% | 119.6% | 198.1% | 31.6% | 152.4% |
| Dividends ÷ net income | 0.0% | 0.0% | 5.8% | 13.5% | 13.6% | 15.0% | 13.5% | 28.8% | 9.0% | 15.7% | 10.7% | 9.6% | 12.1% | 14.0% | 17.3% | 35.7% | 36.2% | 33.6% |
| Dividends and buybacks ÷ free cash flow | 1.9% | 5.3% | 35.9% | 45.1% | 54.8% | 95.8% | 161.4% | 19.9% | 101.6% | 86.8% | 29.9% | 45.8% | 47.1% | 72.1% | 67.3% | 52.2% | 154.9% | 29.8% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 2.5% | −1.9% | 6.3% | 3.4% | 1.2% | −2.5% | 4.4% | 3.3% |
| Net margin | 1.6% | −2.4% | 3.9% | 1.7% | 0.6% | −2.4% | 3.0% | 1.7% |
| Free-cash-flow margin | 5.9% | −2.3% | 0.7% | 3.6% | 2.6% | −5.7% | 2.9% | 4.5% |
| Current ratio | 1.76 | 1.76 | 1.91 | 1.95 | 2.02 | 2.00 | 1.77 | 1.74 |
| Debt to equity | 74.1% | 71.6% | 75.0% | 69.0% | 68.1% | 70.1% | 75.3% | 74.2% |
| SG&A as % of revenue | 11.4% | 14.3% | 10.5% | 11.0% | 12.5% | 13.6% | 10.1% | 9.7% |
Financial health
- Short-term assets cover short-term liabilities $40.1bn of assets due within a year against $23.0bn of liabilities due within a year.
- Short-term assets cover long-term liabilities $40.1bn short-term assets against $14.9bn of longer-dated liabilities.
- More cash than debt $6.9bn of cash against $14.2bn of debt.
- Debt below 40% of shareholders' equity Debt is 74% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 66% to 74% over five years.
- A year's operating cash flow covers at least 20% of debt $2.5bn of operating cash flow against $14.2bn of debt.
- Operating profit covers interest at least five times over Operating income of $2.7bn against $704m of interest.
Moat
Moderate moat
How hard Humana's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 8 / 20
Net income has been a median 5.8% of total assets over 10 years.
- Durability 6 / 20
Operating margin has been a median 4.7%; its worst year was 1.9%.
- Cash conversion 10 / 20
Free cash flow was positive in 9 of 10 years, at a median 2.5% of revenue.
- Discipline 19 / 20
The diluted share count fell 7.9% over five years; stock-based pay has been a median 0.2% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (53 before it).
Compare with peers
- Elevance Health statistics
- Centene Corporation statistics
- UnitedHealth Group statistics
- Molina Healthcare, Inc. statistics
- Oscar Health, Inc. statistics
Head to head: ELV vs HUMCNC vs HUMHUM vs UNHHUM vs MOH
More: Managed Health Care stocks compared, Health Care sector, rankings of US companies